Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Journal
Document Type
Year range
1.
Cornea ; 41(2): 254-256, 2022 Feb 01.
Article in English | MEDLINE | ID: covidwho-1636854

ABSTRACT

ABSTRACT: As the understanding of COVID-19 infection becomes better, it is being recognized as a complex multisystem pathology rather than just affecting the lungs. Several ocular findings have been documented by researchers in individuals infected with COVID-19, and ocular symptoms may even be the first presenting feature of COVID-19 infection in 2.26% individuals. Several countries have started vaccination with inactivated or live vaccines to combat this pandemic, and varied side effects have been reported after vaccination. Few cases of herpes zoster have previously been reported in elderly patients with comorbidities after receiving COVID-19 vaccines. In this article, the authors described 2 interesting cases of herpes zoster ophthalmicus (HZO) after receiving a live COVID-19 vaccine. The first case was a 35-year-old immunocompetent man who developed HZO 3 days postvaccine. The second case was a 40-year-old immunocompetent man who developed HZO 28 days postvaccine. To the best of our knowledge, no literature to date has described HZO after live vaccine.


Subject(s)
COVID-19/prevention & control , ChAdOx1 nCoV-19/adverse effects , Conjunctivitis, Viral/etiology , Herpes Zoster Ophthalmicus/etiology , Vaccination/adverse effects , Acyclovir/therapeutic use , Administration, Ophthalmic , Administration, Oral , Adult , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , Conjunctivitis, Viral/diagnosis , Conjunctivitis, Viral/drug therapy , Drug Therapy, Combination , Herpes Zoster Ophthalmicus/diagnosis , Herpes Zoster Ophthalmicus/drug therapy , Humans , Male , Moxifloxacin/therapeutic use , SARS-CoV-2/immunology , Valacyclovir/therapeutic use , Visual Acuity/physiology
SELECTION OF CITATIONS
SEARCH DETAIL